Skip to content

Basket

You currently have no items in your basket.

AtaGenix

AtaGenix Laboratories specializes in researching and manufacturing customized recombinant proteins and antibodies and have extensive experience in using the five major protein expression systems to satisfy customers' various requirements. AtaGenix's customized antibody platform provides antibody engineering services such as monoclonal/polyclonal antibody customization, recombinant antibody expression, therapeutic antibody development, phage display and antibody humanization. We also utilise our own proprietary CHO-K1 cell line in carrying out research and development of protein and antibody-based drugs. AtaGenix focuses on the development of high-end protein and antibody products. Now the protein series include interleukin, CD molecular, cytokines protein and industrial enzyme, and antibody series like IL molecular antibody, CD molecular antibody and zebra fish antibody.

View All AtaGenix Products
AtaGenix
  • 100% guaranteed
  • Publications
  • Slave free alliance

Antibody Drug Analogues & Biomakers

AtaGenix Laboratories provides a wide range of research grade biosimilar products. Amid the COVID-19 situation, they promise to deliver the production and custom service in time to help the worldwide Covid-related researches.

Find Out More
Antibody Drug Analogues & Biomakers

Why Choose AtaGenix Laboratories

To support assay development and downstream research, AtaGenix Laboratories integrates the company’s reagents and technical expertise to provide a variety of professional detection services. These include performance of mainstream techniques such as Western blotting, immunofluorescence, IHC, and ELISA, in addition to services to generate immunoprecipitation, ChIP, and real-time PCR data.

Why Choose AtaGenix Laboratories


As the main part of the modern biomedical industry, antibody drugs account for about 50% of global biopharmaceutical market. Antibody biosimilars are emerging biopharmaceutic market. Since the best-selling patents for several antibody drugs have expired, this provide an opportunity for antibody-drug analogues.

Antibody-drug analogues and biological original drugs contain similar active substances, which are similar in quality, safety and effectiveness, there is no difference in clinical significance. On November 7, 2019, the first adalimumab biosimilar drug BAT1406 was approved for marketing in China, which accelerated the development of antibody drugs. AtaGenix is now launching antibody-drug analogues to support the development of antibody drugs.